Drug Trial Radar · NCT05731752
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
May 28, 2020
Primary completion
Dec 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, multiple-dose administration dose exploratory clinical phase I study to evaluate the safety, tolerability, and PK profile of HX009 Injection in patients with advanced solid tumors and to provide a preliminary measure of its antitumor efficacy. It includes Phase Ia and Phase Ib. phase Ia is a dose exploratory study to evaluate safety, tolerability, and to determine the MTD and/or RP2D.The sponsor and investigator will adjust the magnitude of the dose escalation and the dosing cycle based on the safety and tolerability of HX009 Injection and the PK data that have been obtained, as well as decide whether to add an unplanned dose or dosing cycle to the trial, and recommend the RP2D.The Ia phase dose escalation design model is shown below. The planned dosing cycle for this study is once every 2 weeks (14 days) (Q2W) with IV HX009. Based on the result of phase 1a,10 mg/kg Q2W was the recommended dose for phase 1b. The aimed population for 1b is patients diagnosed with advanced melanoma, and divided into two cohorts:: cohort A ,untreated patients with unresectable or metastatic advanced melanoma;and Cohort B, patients with unresectable or metastatic malignant melanoma that had been treated with immune checkpoint inhibitor therapy. The enrollment of Cohort B will start first.,and whether the cohort A will be initiated depends on the results of the cohort B .The up to 80 patients will be enrolled in Phase Ib.
Conditions
- Advanced Solid Tumors
Interventions
HX009Drug
The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
Primary outcomes
What the sponsor says the trial is designed to measure.
- In phase Ia: Incidence of Dose Limiting Toxicities (DLT) of HX009 in patients with advanced solid tumorsTime frame: At the end of Cycle 2 (each cycle is 14 days)
- Incidence of adverse events (AE) of HX009 in patients with advanced solid tumorsTime frame: Collected adverse events from signing of informed consent through at least 28 days after the end of treatment, or until other cancer treatment regimens have been started (whichever occurs earlier).
- In phase IB:Incidence of Dose Limiting Toxicities (DLT) in HX009 in patients with advanced solid tumorsTime frame: At the end of Cycle 2 (each cycle is 14 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciense
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.